Compare CYD & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | DMRA |
|---|---|---|
| Founded | 1951 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | 7 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1998 | 2020 |
| Metric | CYD | DMRA |
|---|---|---|
| Price | $54.68 | $25.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $60.00 | $43.00 |
| AVG Volume (30 Days) | 193.2K | ★ 318.6K |
| Earning Date | 02-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.11 | N/A |
| Revenue Next Year | $8.67 | N/A |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.77 | $16.50 |
| 52 Week High | $61.48 | $28.76 |
| Indicator | CYD | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 52.46 |
| Support Level | $35.24 | $24.80 |
| Resistance Level | $56.55 | $26.73 |
| Average True Range (ATR) | 3.00 | 1.51 |
| MACD | 0.59 | 0.12 |
| Stochastic Oscillator | 58.48 | 74.94 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.